Jarred Michael Scaffidi-Muta, Kwong Ching Li, Didier Boucher, Thomas Kryza, William Tieu, Andrew David Abell
{"title":"用于203/212Pb治疗对的双功能谷氨酸衍生螯合剂的合成和体内评价。","authors":"Jarred Michael Scaffidi-Muta, Kwong Ching Li, Didier Boucher, Thomas Kryza, William Tieu, Andrew David Abell","doi":"10.1186/s41181-026-00473-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the <sup>203/212</sup>Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).</p><h3>Results</h3><p>DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with <sup>212</sup>Pb and <sup>203</sup>Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb<sup>2+</sup> complexation than TCMC-MC1RL. Both <sup>212</sup>Pb-labelled compounds remained > 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.</p><h3>Conclusions</h3><p>DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of <sup>203/212</sup>Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616893/pdf/","citationCount":"0","resultStr":"{\"title\":\"Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203/212Pb theranostic pair\",\"authors\":\"Jarred Michael Scaffidi-Muta, Kwong Ching Li, Didier Boucher, Thomas Kryza, William Tieu, Andrew David Abell\",\"doi\":\"10.1186/s41181-026-00473-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the <sup>203/212</sup>Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).</p><h3>Results</h3><p>DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with <sup>212</sup>Pb and <sup>203</sup>Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb<sup>2+</sup> complexation than TCMC-MC1RL. Both <sup>212</sup>Pb-labelled compounds remained > 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.</p><h3>Conclusions</h3><p>DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of <sup>203/212</sup>Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.</p></div>\",\"PeriodicalId\":534,\"journal\":{\"name\":\"EJNMMI Radiopharmacy and Chemistry\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2026-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616893/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Radiopharmacy and Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s41181-026-00473-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/9/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-026-00473-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203/212Pb theranostic pair
Background
The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the 203/212Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).
Results
DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with 212Pb and 203Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb2+ complexation than TCMC-MC1RL. Both 212Pb-labelled compounds remained > 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.
Conclusions
DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of 203/212Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.